# Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

> **NCT03325621** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pieris Pharmaceuticals GmbH** · enrollment: 11 (actual)

## Conditions studied

- Anemia of Chronic Kidney Disease

## Interventions

- **BIOLOGICAL:** PRS-080#022-DP
- **BIOLOGICAL:** PRS-080-Placebo#001

## Key facts

- **NCT ID:** NCT03325621
- **Lead sponsor:** Pieris Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-30
- **Primary completion:** 2019-03-30
- **Final completion:** 2019-06-30
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325621, "Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03325621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*